As type I interferons (IFNs) enhance the stimulatory activity of dendritic cells (DCs), we hypothesized that transfection of glioma cells with the IFN-b gene in the presence of DCs would provide particularly effective antitumor activity by both facilitating apoptosis of glioma cells and presenting the resulting glioma antigens to T cell by DCs, thereby inducing specific T-cell responses against glioma cells. A mouse glioma cell line 203G was first transfected with cDNA encoding IFN-b using cationic liposomes, then cocultured with syngeneic bone marrow-derived DCs and naïve splenic T cells. The 203G cells were almost completely killed following 96-hour coculture with DCs and T cells, and strong tumor-specific cytotoxic T-lymphocyte (CTL) activity accompanied by high level interleukin (IL)-12 and IFN-g production was observed in culture. In addition, omission of either IFN-b gene delivery, DCs or T cells from the coculture completely abrogated the induction of the CTL activity, suggesting that the combination of these components was required to elicit an optimal effect. On the basis of these in vitro data, syngeneic animals bearing subcutaneous 203G tumors received intratumoral injections of IFN-b gene and DCs. Suppression of the tumor growth by this combinational therapy was superior to treatment with DC or IFN-b gene solely. This combination may constitute a new therapeutic strategy to induce potent antiglioma immune responses.
T ype I interferons (IFNs), including IFN-a and IFN-b, have several functions, such as inhibition of viral replication and proliferation of neoplastic cells. [1] [2] [3] Although the IFN-b protein has been used therapeutically for patients with malignant gliomas by intravenous or intrathecal administration and its safety has been demonstrated, [4] [5] [6] it has been difficult to achieve effective cytokine levels within the tumor at clinically tolerated doses. In an effort to target the expression of this cytokine to the tumor cells themselves, we developed a novel gene transduction system using cationic liposomes containing IFN-b expression plasmid and have reported the efficacy of IFN-b gene transfer in preclinical glioma models. 7, 8 In these studies, cationic liposome-mediated IFN-b gene transfer inhibited tumor growth more effectively than administration of equivalent, or even higher concentrations of exogenous IFN-b protein. 8 The effect of IFN-b produced by transfected glioma cells appeared to involve a direct cytotoxic effect on glioma cells that was dependent on intracellular cytokine activity. 7 In addition, intratumoral delivery of the IFN-b gene promoted antiglioma cytotoxic T-lymphocyte (CTL) activity as well as natural killer (NK) cells without significant toxicity. [9] [10] [11] These data suggest that IFN-b gene transfer may be an effective and safe strategy whereas some other cytokines have been toxic when delivered to the intracranial tumors. 12, 13 In addition to their cytotoxic effects on selected tumor cells, IFN-b and other type I IFNs are known to have broader effects on the immune system by influencing the function and phenotype of dendritic cells (DCs), 14, 15 which are the most potent antigen-presenting cells. [16] [17] [18] For example, type I IFNs promote the generation and maturation of the DCs, comparable to the effects observed with interleukin (IL)-4. 19, 20 IFN-b upregulates tumor necrosis factor-a (TNF-a)-related apoptosis-inducing ligand (TRAIL) expression on DCs, thereby facilitating the antitumor activity of the DCs via TRAIL. 15 In addition, recent studies indicated that in vitro treatment of DCs with type I IFN enhances the antigen-presenting capability of DCs.
antitumor T-cell responses, and both necrotic 22 and apoptotic tumor cells [23] [24] [25] are known to be good antigen sources for DCs, we hypothesized that transfection of glioma cells with IFN-b in the presence of DCs would provide a way to not only achieve an ideal glioma antigen source for DCs, but also facilitate the presentation of these glioma-derived antigens to T cells. In this study, we analyzed the role of DCs 
Materials and methods

Production of a murine IFN-b expression vector plasmid
The cDNA encoding murine IFN-b was obtained from pSV2-IFNb, 7, 8 and was subcloned into a retroviral vector plasmid, pDONAI (Takara Bio Inc, Otsu, Shiga, Japan). This vector plasmid has a cytomegalovirus immediateearly (CMV-IE) promoter and enables effective gene expression. This expression plasmid encoding murine IFN-b was termed DONAI-IFN-b. As a comparison, an expression plasmid encoding murine IL-12 (pCMV-IL12) was used in some experiments.
Tumor cell line
The 203G mouse glioma cell line, derived from a C57Bl/6 mouse, [26] [27] [28] [29] was maintained in media composed of RPMI1640 (Invitrogen, Carlsbad, CA) supplemented with 10% heat-inactivated fetal bovine serum, penicillin/ streptomycin and l-glutamine, in a humidified atmosphere at 371C and 5% CO 2 .
Transfection of murine IFN-b gene by cationic liposome
Aliquots of 2 Â 10 4 203G cells were seeded in each well of 24-well plates and cultured for 24 hours before transfection with 0.8 mg/well plasmid DNA admixed with 12.5 m/well cationic liposomes (DOTAP, Roche, Indianapolis, IN). At 6 hours after transfection, 203G cells were washed with phosphate-buffered saline (PBS) twice, then subjected to coculture with DCs and T cells as noted below. The level of IFN-b expression from 2 Â 10 4 transfected 203G cells was determined to be approximately 300 IU/ml per 48 hours.
Preparation of bone marrow-derived DCs and spleen-derived T cells
To obtain DCs, bone marrow cells harvested from femurs and tibias of C57Bl/6 mice were cultured in six-well plates (4 Â 10 5 cells/well) in 4 ml of mouse complete media (CM) containing 1000 IU/ml recombinant murine GM-CSF and IL-4, and incubated under humidified atmosphere at 371C and 5% CO 2 as previously described. 25, [30] [31] [32] On day 6, CD11c + DCs were enriched from the bulk bone marrow culture using a magnet-assisted cell sorting (MACS) system with magnetic beads conjugated to anti-CD11c antibody (Miltenyi Biotec Inc., Auburn, CA). On the same day, spleens were harvested from C57Bl/6 mice and homogenized in CM to obtain T lymphocytes. Thy1.2 + T cells were enriched from nylon wool nonadherent splenocytes using an MACS system with magnetic beads conjugated to anti-CD90 (Thy1.2) antibody. 33, 34 Flow cytometric analyses demonstrated that the purity of enriched CD11c + DCs and Thy 1.2 + T cells was higher than 80 and 90%, respectively (data not shown). These cells were used throughout this study as DCs and T cells, respectively.
Observation of cell death or growth inhibition induced by interplay of IFN-b gene transfer, DCs and T cells under VEC-DIC microscopy
Glioma cell death and growth inhibition were analyzed morphologically with a video-enhanced contrast-differential contrast (VEC-DIC) microscopy system, as described. 35, 36 The living cells were observed with an inverted Nomarski microscope equipped with DIC objective lens and 2.5 insertion lens (Axiobert 135, Carl Zeiss, Germany). The microscopic image was sent to an image processor and controller (C2400, Hamamatsu Photonics, Japan) via 0.5 in charge-coupled device (CCD) camera. Digital image signals from microscope were enhanced mainly in contrast. The processed images were recorded on a video laser disk (LVR-3000AN, SONY, Japan). 203G cells were incubated in glassbottomed culture dishes (P35G-0-14-C, MatTec, USA) at 371C in a humidified atmosphere of 5% CO 2 for 24 hours, followed by liposomal transfection with IFN-b and coculture with DC and T cells. CO 2 concentration in the observation chamber was maintained with a CO 2 Inject Control Timer (Kokensha Co. Ltd, Japan), thereby allowing continuous observation of the cultured cells through VEC-DIC microscopy.
In vitro cytokine release and CTL assays
Cytokine production was assessed in the cocultures, which consisted of 2 Â 10 4 203G cells that had been cultured for 6 hours after genetransfection, 4 Â 10 5 DCs and 4 Â 10 6 T cells in CM containing 300 mm N Gmonomethyl-l-arginine (l-NMMA, Cyclops Biochem, Salt Lake City, UT) and 10 IU/ml recombinant human IL-2 in each well of the 24-well plates. Control groups included a group that contained 1000 IU/ml recombinant murine IFN-b (Toray Industry, Kamakura, Japan) instead of IFN-b gene transfection, a group in which the glioma cells were transfected with a backbone plasmid, and groups that lacked DCs. Following the coculture for 40 or 96 hours, supernatant was collected for determining the concentration of IL-12 p70 and IFN-g using enzymelinked immuno-specific absorbent (ELISA) assays using OptEIA kits (BD PharMingen, San Diego, CA). The minimum detection limit of these assays was 31.3 pg/ml for each of the cytokines.
Cytolytic activity of the T cells was also assessed after 96 hours of culture. Cells were harvested from the cocultures using Ficoll purification, and tested in a standard 4 hours 51 Cr release assay as previously described. 37 
Intratumoral delivery of IFN-b gene and DCs in subcutaneous tumors
Each of C57Bl/6 mice was injected with 2 Â 10 6 203G cells suspended in 100 ml in PBS in the right flank on day 0. At 2 weeks after tumor inoculation, animals received intratumoral injection with 1 mg DONAIIFN-b or control backbone plasmid in 30 ml DOTAP solution using a 50 ml Hamilton syringe. On day 16, animals were injected intratumorally with bone-marrow derived, CD11c + , day 6 DCs (5 Â 10 5 cells in 30 ml PBS) or control PBS using a 50 ml-Hamilton syringe. Each group consisted of five animals and tumor size was monitored by measuring the longest axis and perpendicular axis in a blind fashion, and recorded according to the following formula:
Tumor volume ¼ 0:5 Â ðlength Â width 2 Þ:
All animal experiments were performed according to the guidelines of the Institutional Animal Care and Use Committee (IACUC) of University of Pittsburgh and the principles laid down in the ''Guide for the Care and Use of Laboratory Animals''.
Statistical analyses
Unpaired two-tailed Student's t-test was used to compare the levels of cytokine expression and cytotoxic activity of the T cells. Mann-Whitney test was used to compare the tumor volumes between the groups in the animal study. A P-value less than .05 was considered to be a significant difference. (Fig 1a) in comparison with the control wells that received mock transfection (Fig 1b) or 1000 IU/ml recombinant mouse IFN-b (Fig 1c) . It was noted that IFN-b gene transfer resulted in the death of some glioma cells, which were found as shrinking and As the course advances, nuclei were condensed at around 40 hours (f). Subsequently, the tumor cells showed balloon-like appearance at around 48 hours (g), and detached from dish bottom. These changes are consistent with apoptotic cell death. 36 Induction of antiglioma CTL by IFN-beta gene transfer N Nakahara et al floating cells in the culture (Fig 1a) . To further examine the kinetics of the cytotoxic effect induced by IFN-b gene transfer, the cells were observed with the VEC-DIC microscope at various time points following liposomal transfection with IFN-b (Fig 1d-g ). Approximately 20% of the 203G glioma cells underwent morphological changes including shrinkage, formation of blebs, nuclear condensation and ballooning at 16-48 hours after transfection. These morphological changes were consistent with apoptosis. 36, 38 However, the majority of the cells were unaffected. This discrepancy of the cell viability within the same culture was thought to reflect the efficacy of the liposomal transfection we employed, in that about 20% of the cells produced detectable levels of transgene, as assessed by a control plasmid encoding green fluorescence protein (data not shown). These findings suggested that the antiglioma effect induced by IFN-b gene delivery itself might not be sufficient to achieve significant therapeutic efficacy in vivo in the absence of 100% transfection efficacy, which would be impractical to achieve in a clinical context. (Fig 2e) , almost all the tumor cells were observed to be either dead or dying after 96 hours of coculture. Approximately 300 IU/ml IFN-b was detected in each of the cultures that received liposomal transfection with IFN-b plasmid (not shown).
Results
Transfection
In contrast, replacement of the IFN-b gene transfection with PBS (Fig 2a) , with 1000 U/ml exogenous recombinant IFN-b (Fig 2b) , liposome without DNA (empty liposome) (Fig 2c) , or with liposomal transfection with a backbone control plasmid (Fig 2d) , abrogated the antitumor response significantly, and there was approximately 70-100% confluence of adherent tumor cells despite the presence of DC and T cells. Similarly, when the coculture received the IFN-b gene and T cells but not DCs (Fig 2f) , significant antitumor effect was not observed. These data indicate that the combination of these three factors was necessary to achieve a potent antitumor effect.
Rapid induction of IL-12 production and specific CTL responses in the coculture following IFN-b gene transfer
Such an effective eradication of glioma cells in the coculture presented in Figure 2 led us to examine the cytokine responses in the cocultures following IFNb transfection. We first examined production of IL-12 p70, as the biologically active form of IL-12, because the data presented in Figure 2 suggested an important role of DCs, and IL-12 is known to be a key cytokine that is produced by DCs in the induction of specific immune responses. 39, 40 IL-12 is a potent IFN-g inducer and critical facilitator of T-helper 1 (Th1) type responses, associated with strong CTL-mediated immunity. 41, 42 Supernatant was harvested at 40 and 96 hours after initiation of cocultures. As demonstrated in Figure 3 , transfection of glioma cells with IFN-b gene induced significant levels of IL-12 and IFN-g in the supernatant, but only in the presence of DCs, and this occurred as early as at 40 hours after initiation of coculture. None of the control groups, including those stimulated with recombinant IFN-b, instead of gene transfer, produced significant levels of IL-12 or IFN-g. In the IFN-b gene-treated group, the concentration of IL-12 in the culture did not change significantly at 96 hours compared to 40 hours, whereas IFN-g concentration continued to increase in concentration up to 96 hours, suggesting that the production of IL-12 from DC was a relatively transient phenomenon that probably occurred during the early period after initiation of coculture, consistent with previous observations by others 43 . Remarkable induction of IL-12 p70 production in the coculture composed of IFN-b gene-transfected 203G cells, DCs and T cells (Fig 3a) led us to examine whether transfection with IL-12 gene could substitute the role of IFN-b gene transfer in the induction of an antiglioma response. Transfection of 203 with CMV-murine IL-12 plasmid resulted in production of approximately 2000 pg/ml IL-12 p70 (data not shown), which is four to five times higher than the levels achieved by endogenous expression following IFN-b gene transfer; however, IFN-g levels were similar to those induced by IFN-b transfection (Fig 3b) . Transfection with IL-12 gene appeared to induce some level of IFN-g even without DCs, probably because of the direct induction of IFN-g from T cells by transgene-derived IL-12.
To examine the induction of tumor-specific CTL responses in these cultures, the nonadherent live cells were harvested from the day 4 cocultures and subjected to 4 hours 51 Cr-release assay to assess specific cytotoxic activity. The effector cells derived from the coculture composed of IFN-b gene-transduced glioma cells, DCs and T cells demonstrated significant anti-203G tumorspecific CTL activity only after 4 days of stimulation (Fig 4a) . None of the control groups exhibited any significant level of anti-203G CTL activity.
Although IL-12 gene transfer supported the development of a detectable level of CTL activity, the level was lower than in the group treated with IFN-b gene transfer, suggesting that ectopic expression of transgene-derived IL-12 is not sufficient to replace the role of IFN-b gene transfer.
Recombinant IFN-b of equivalent or even higher concentration was also not able to replace the effect of IFN-b gene transfer. In the IFN-b transfection groups, the approximate concentration of IFN-b at 48 hours following transfection was approximately 300 IU/ml (data not shown), and 1000 IU/ml recombinant IFN-b failed to induce a CTL response. To examine whether a higher or lower dose of recombinant IFN-b can induce CTL responses, we also tested doses between 100,000 and 50,000 IU/ml, but none of these conditions succeeded in inducing a significant CTL response (data not shown). The absence of DCs in these cultures resulted in a complete failure to support the induction of response (Fig 4b) . 
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In order to confirm that the CTL response was against 203G cells in the context of MHC class I restriction, specific blocking assays were performed using an anti-H-2D b mAb (Fig 4c) . The CTL activity against 203G cells, which was induced in the coculture of IFN-b-transfected 203G cells, DCs and T cells, was abrogated by blocking of MHC class I signaling, suggesting the CTL activity was H-2D b -restricted. These results suggest that the potent antitumor effect that was observed in the presence of DCs and T cells was mediated by rapid induction of a potent and specific CTL activity within 4 days following in vitro sensitization with tumor cells transfected with IFN-b cDNA.
Inhibition of in vivo tumor growth by intratumoral injection of IFN-b gene and DCs
In order to translate our in vitro observations to a treatment for in vivo tumors, we treated syngeneic C57Bl 
Discussion
In the present study, we have demonstrated the effective in vitro induction of specific CTL responses using cultures that combine IFN-b cytokine gene transfer in a murine Cytokine gene therapy for gliomas appears to have a promising future, based on encouraging results in murine models, 9 although the efficacy remains inferior to that observed in systemic tumor models. This may reflect the fact that the central nervous system represents an immunologically challenging environment, 44 at least, partially because of a paucity of professional antigenpresenting cells under normal circumstances. 45 Our previously reported analyses of tumor-infiltrating lymphocytes (TILs) derived from cytokine gene-transfected 9L rat glioma lesions revealed a lower density of TILs in intracranial tumors compared to subcutaneous tumors, 46 suggesting the necessity of modifying the immunological microenvironment in the brain tumor site in order to improve the efficacy of immunotherapeutic approaches. Indeed, local cytokine expression at the brain tumor site increased the density of the TILs and prolonged the survival of the animals to some extent. 46 Our data in the present study provide new insights for the development of future strategies to modify the tumor microenvironment in order to induce effective antitumor immunity through the combined delivery of the IFN-b gene and DCs.
In our morphological analyses of tumor cells following IFN-b gene transfection (in the absence of adding DCs or T cells), we observed that approximately 20% of the 203G cells underwent morphological changes consistent with apoptosis. In our preliminary assessment of the sensitivity of glioma cell lines to liposomal transfection with IFN-b, we found that some cell lines, such as GL261 cells, were more sensitive and underwent cell death to a greater extent than 203G cells (data not shown). This differential sensitivity to engineering-induced apoptosis may have contributed to the comparative therapeutic efficacy of liposomal IFN-b gene delivery alone in syngeneic animal models bearing intracranial GL261 tumors. 9 Variable sensitivity to human IFN-b has also been observed in human glioma cell lines. 47 Given the highly heterogeneous nature of human malignant gliomas, our intent is to develop strategies to improve the efficacy of IFN-b gene therapy, regardless of the sensitivity of individual glioma cells to IFN-b itself. Hence, we chose the 203G line as a preferred model, as it is relatively resistant to the direct growth suppression or cytotoxic effects of IFN-b gene transfer, and may reflect a more stringent scenario germane to human disease. Accordingly, only minimum growth suppression was seen in the 203G cells that were treated with IFN-b gene transfer alone, whereas the addition of both DCs and naı¨ve T cells eliminated most of the 203G cells via a mechanism consistent with specific CTL activity. Evidence of IL-12 induction in the early phases of coculture indicated the appropriate activation of DCs. With regard to the maturation stage of DCs, we used relatively immature DCs that were derived from bone marrow and cultured in the presence of GM-CSF and IL-4 for 6 days, 48 since immature DCs are believed to be efficient in taking up foreign antigens by phagocytosis 24 and would be anticipated to cross prime antitumor T cells under such conditions. As for IL-12 production after in vitro stimulation, the ability of DCs to produce IL-12 declined early in the in vitro sensitizations, as we did not see an increase of IL-12 p70 at 40 and 96 hours after the initiation of the cocultures. This phenomenon is consistent with reports for the cessation of IL-12 p70 production by DCs after being stimulated by T cells or CD40 ligation. 49, 50 In these studies, DCs producing IL-12 promoted the development of Th1 cells from naı¨ve T cells, whereas DCs that were poor producers of IL-12 induced predominantly memory T cells and Th2 cells. This information provides insights into relevant strategies for designing potentially more effective DC-based immune modulations. Therapeutic vaccines against existing cancers may have to direct the generation of large numbers of type -1 effector cells. Based on our findings in the present study, further studies are warranted to compare the immune response using DCs of different maturation stages in order to optimize the responses favored for the treatment of intracranial brain tumors.
It remains to be investigated how IFN-b gene transfection, and not use of recombinant IFN-b, induces tumor apoptosis and the induction of specific CTL responses when DCs and T cells were added in these cultures. We believe that the induction of apoptosis in the glioma cells is a combinational effect of both the transfection with IFN-b cDNA (i.e. endogenous expression of the transgene) and a direct effect of secreted IFN-b protein based on the following observations by others and our recent preliminary data.
It has been demonstrated by others that constitutive weak expression of endogenous type I IFNs enhances the transactivation of type I IFNs-signaling pathways and potentiates robust antiviral and antitumor responses upon secondary type I IFN-stimuli (reviewed by Taniguchi 51 ). Activation of the Janus kinases (Jak) signal transducer With regard to the roles of IFN-b gene transfer and DCs in the induction of CTL responses, we believe that DCs may take up tumor cells induced to undergo apoptosis as a result of gene transfer, and that these antigen-loaded DCs may then cross-present gliomaderived antigens to specific T cells. This is consistent with previous reports by others that have documented that DCs phagocytose apoptotic bodies and can subsequently effectively present antigens derived from these apoptotic bodies. 23, 48 We also believe that transgene-derived IFN-b in our culture system plays an important role in facilitating the induction of CTLs through a variety of mechanisms, such as the induction of the Th1-biasing cytokine IL-12p70 from DCs.
It has been previously shown that a combination of IL-18, NK cells, DCs and T cells rapidly induces CTL and IFN-g responses in vitro; 52 however, this reported system requires the inclusion of NK cells, which might be potent producers of IFN-g. In our system, although type I IFNs are known to induce IFN-g production in human but not in mouse T cells (reviewed in O'shea et al 53 ] we believe that IFN-g production predominantly results in response to IL-12 elaborated by DCs. Further investigations are warranted to elucidate the detailed effects of IFN-b gene transfection on DC functions.
Lastly, our results from the treatment of subcutaneous 203G tumors suggest that this combination strategy may be efficacious for the in vivo therapy of tumors, whereas single treatment with DCs or IFN-b gene are likely to exert minimal effects as single agents. While this is consistent with our in vitro observations, we are aware that endogenous antigen-presenting cells may become activated by injection of IFN-b plasmid admixed with liposomes. However, such endogenous monocytes and macrophages in the tumor microenvironment are likely to be severely suppressed in their function because of the variety of mechanisms with which tumors escape host immunity. In particular, malignant gliomas are known to elaborate high concentrations of immunosuppressive substances, such as TGF-b. [54] [55] [56] [57] Transfection of human glioma cells with the IFN-b gene does not appear to suppress the secretion of TGF-b (unpublished data), by tumor cells, suggesting that IFN-b gene transfer by itself may not dramatically correct the overall immunosuppressive environment of gliomas. A recent study has indicated that IL-4 prevents the blockade of DC differentiation induced by tumor cells. 58 Introduction of exogenously activated DCs that are cultured with GM-CSF and IL-4, therefore, may be necessary to overcome the suppressed host-defense mechanisms.
As a logical extension of our findings, we have developed strategies to deliver IFN-b gene and DCs within the brain tumor site. Although there are significant numbers of microglia/macrophage that infiltrate the brain 59, 60 and the brain tumor site, 61 the antigenpresenting ability of those cells is controversial. [62] [63] [64] Immunosuppression by glioma-derived substances such as TGF-b may impair the function of DCs. 65 It will be intriguing to examine whether the addition of DC delivery to IFN-b gene therapy will overcome the immunosuppressive environment of the central nervous system tumors, and induce therapeutic immune responses.
Furthermore, the combination of this approach with peripheral vaccine strategies may further enhance therapeutic efficacy by promoting the activity and survival of immune effector cells, which are primarily induced in the periphery. 30, [66] [67] [68] [69] Abbreviations IFN, interferon; DC, dendritic cell; CTL, cytotoxic T cell; IL, interleukin; TNF, tumor necrosis factor; NK, natural killer; TRAIL, tumor necrosis factor-a (TNF-a)-related apoptosis-inducing ligand; Neo-R, neomycin resistant gene; VEC-DIC, video-enhanced contrast-differential contrast; CM, complete media.
